NZMP and Maypro have entered into an agreement in which Maypro will be an authorized reseller of NZMP’s BifidoB HN019 and LactoB HN001 probiotic strains in North America, as well as new strains in development.
NZMP (Chicago, IL) and Maypro (Purchase, NY) have entered into an agreement in which Maypro will be an authorized reseller of NZMP’s BifidoB HN019 and LactoB HN001 probiotic strains in North America, as well as new strains in development. The strains were first discovered and commercialized by NZMP’s parent company, Fonterra. They have been extensively researched with over 60 combined human clinical trials which have shown a range of consumer benefits, including digestive health, immunity, skin health, women's health and post-natal depression. NZMP’s probiotic strains have comprehensive certifications including vegan, vegetarian, non-dairy, organic, halal, kosher and non-GMO project verified, as well as proven stability in a range of dosage formats such as capsules and sachets, yogurts, ice creams, chocolate and coatings and high-pressure processed juices.
"This agreement with Maypro is important to brands already using probiotic ingredients as well brands looking to develop new products with health claims in mood, stress, anxiety, skin health, digestive health and immunity," says Chris Ireland, senior manager business development, NZMP, in a press release. "This agreement will allow us to both extend our sales force and harness Maypro's valuable supplement customer network."